FundaMeric-BernstamMD

Surgical Oncology (Other than Breast)

Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy Nellie B. Connally Chair in Breast Cancer Research Professor, Division of Cancer Medicine and Surgery

Join to view full profile

Dr. Meric-Bernstam is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Meric-Bernstam's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Fax+1 713-745-7296

Education & Training

University of MichiganResidency, Surgery, 1991 - 1998
Yale School of MedicineClass of 1991

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 1999 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
WA State Medical License 2023 - 2025
MI State Medical License 1996 - 2000
American Board of Preventive Medicine Clinical Informatics
American Board of Surgery Surgery
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

Bevacizumab in Multiple Phase I Combinations Start of enrollment: 2007 Oct 10
Completed
Phase 1
Axillary Reverse Mapping for Invasive Carcinoma of the Breast Start of enrollment: 2008 Mar 01
Completed
Phase 1
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy Start of enrollment: 2009 Mar 30
Active, not recruiting
Phase 2
Fluorescent Dyes for Lymph Node Mapping Start of enrollment: 2010 Mar 01
Completed
Phase 1
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer Start of enrollment: 2011 Jan 05
Completed
Phase 1
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer Start of enrollment: 2011 Mar 01
Completed
Phase 2
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program Start of enrollment: 2012 Mar 01
Recruiting
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Start of enrollment: 2013 Oct 01
Terminated
Phase 2
A Study of TAS-120 in Patients With Advanced Solid Tumors Start of enrollment: 2014 Jul 21
Completed
Phase 1, Phase 2
Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19
Recruiting
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 01
Terminated
Phase 1, Phase 2
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors Start of enrollment: 2019 Jan 24
Active, not recruiting
Phase 1
A Study in Patients With Advanced Cancers Start of enrollment: 2022 Mar 25
Recruiting
Phase 1, Phase 2
Roles: Contact
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression Start of enrollment: 2021 Sep 21
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Approved for marketing
Roles: Contact
First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Start of enrollment: 2023 Jan 11
Recruiting
Phase 1
Roles: Contact
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer Start of enrollment: 2020 Oct 15
Recruiting
Phase 1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models.
Funda Meric-Bernstam, Erkan Yuca, Kurt W Evans, Ming Zhao, Takanori Maejima
Clinical Cancer Research. 2024-11-25
Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer.
Luisa E Jacomina, David M Swanson, Melissa P Mitchell, Wendy A Woodward, Benjamin D Smith
International Journal of Radiation Oncology, Biology, Physics. 2024-11-15
Utilizing Patient-derived Xenografts to Model Precision Oncology for Biliary Tract Cancer.
Timothy P DiPeri, Kurt W Evans, Stephen Scott, Xiaofeng Zheng, Kaushik Varadarajan
Clinical Cancer Research. 2024-11-08

Lectures

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
2019 ASCO Annual Meeting - 6/1/2019
Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Single agent activity of ZW25, a HER's targeted bispecific antibody, in heavily pretreated HERs' expressing cancers.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Symposia on Cancer Research 2013
The University of Texas, M. D. Anderson Cancer Center, Houston, Texas - 10/4/2013
Symposia on Cancer Research 2013
The University of Texas, M. D. Anderson Cancer Center, Houston, Texas - 10/4/2013
Somatic Mutation Testing and Opportunities for Clinical Interventions
Houston, TX - 10/28/2014
Join now to see all

Press Mentions

Novel ADC AZD8205 Demonstrates Manageable Safety Profile and Preliminary Efficacy in First-in-Human TrialSeptember 13th, 2024
MD Anderson Research Highlights for May 8, 2024May 8th, 2024
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast CancerDecember 8th, 2022
Join now to see all